BC Cancer Extravasation Hazard Table

VESICANT	NONVESICANT	
	IRRITANT	**NONE**	
amsacrine	arsenic trioxide	aldesleukin	lanreotide
busulfan	azaCITIDine	alemtuzumab	leucovorin
carmustine	bendamustine	asparaginase	leuprolide
DACTINomycin	brentuximab vedotin†	atezolizumab	mesna (diluted)
DAUNOrubicin	bortezomib	avelumab	methotrexate
DOXOrubicin	CISplatin	BCG	methoxsalen
epirubicin	dacarbazine	bevacizumab	octreotide
IDArubicin	DAUNOrubicin-cytarabine liposome	bleomycin	oBINutuzumab
melphalan	DOCEtaxel	blinatumomab	nivolumab
mitomycin	DOXOrubicin pegylated liposomal	buserelin	pamidronate
streptozocin	enfortumab vedotin†	cabazitaxel	PANitumumab
trastuzumab emtansine	etoposide	CARBOplatin	pegaspargase
vinBLAStine	etoposide phosphate	carfilzomib	peginterferon alfa-2a
vinCRIStine	fluorouracil	cemiplimab	pembrolizumab
vindesine	gemcitabine	cetuximab	pemetrexed
vinorelbine	ifosfamide	cladribine	PERTuzumab
	mesna (undiluted)	clodronate	plerixafor
	mitoXANTRONE	cyclophosphamide	pralatrexate
	oxaliplatin*	cytarabine	ramucirumab
	PACLitaxel*	daratumumab	raltitrexed
	PACLitaxel-nab*	degarelix	riTUXimab
	polatuzumab vedotin†	denosumab	romiDEPsin
	teniposide	dexrazoxane	sacituzumab govitecan
	treosulfan	dinutuximab	sargramostim
		durvalumab	siltuximab
		eriBULin	tebentafusp
		filgrastim	temsirolimus
		fludarabine	testosterone
		fulvestrant	thiotepa
		gemtuzumab ozogamicin‡	thyrotropin alfa
		goserelin	topotecan
		inotuzumab ozogamicin	trastuzumab
		ipilimumab	trastuzumab deruxtecan
		irinotecan	zoledronic acid
		isatuximab	

*Follow specific procedures in Systemic Therapy Policy III-20 if extravasated.
†Contain potentially vesicant component but no reported cases of tissue necrosis or ulceration after extravasation
‡Some case reports of extravasation and injection site reactions or inflammation have been reported.

For definitions of different categories of extravasation hazard and the details on management of extravasation, see BC Cancer Systemic Therapy Policy III-20 Prevention and Management of Extravasation of Chemotherapy.